Glenmark confirms Vimpat challenge
Pharmaceutical company Glenmark Generics has confirmed that it has filed ANDAs with the US FDA to market generic versions of epilepsy drug Vimpat.
IPAB rejects Monsanto plant patent
India’s Intellectual Property Appellate Board has affirmed that US agricultural company Monsanto cannot obtain a patent covering transgenic plants, two years after it was first rejected.
Australian bid for OxyContin generic dismissed
The Federal Court of Australia has dismissed Spirit Pharmaceutical’s bid to introduce a generic version of painkiller OxyContin.
Greenberg Traurig names new IP co-chair in Boston
US law firm Greenberg Traurig has appointed shareholder Jennifer Camacho as co-chair of its Boston IP group.
Myriad sues Ambry over cancer gene screening tests
Biotech company Myriad Genetics has filed a patent infringement case against Ambry Genetic Corp for allegedly infringing 10 patents related to genetic diagnostic testing.
FDA stings thousands of fake drug sites
The US Food and Drug Administration (FDA) last month seized and shut down 1,677 illegal pharmacy websites selling $41,104,386 worth of fake medicines.
Novartis strikes vaccine licensing deal with Indian biopharma
Novartis has signed a development and licensing agreement with Indian biopharmaceutical company Biological E Limited (BioE) to deliver two vaccines that protect against typhoid and paratyphoid fevers.
EU court overrules commission in Orphacol drug case
The General Court of the European Union has annulled the European Commission’s decision to refuse marketing authorisation for orphan drug Orphacol.
UCB challenges Teva generic drug application
Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.
AbbVie triumphs in Humira case
Pharmaceutical company AbbVie has won a patent case against UK research body The Kennedy Institute of Rheumatology Trust relating to the arthritis medication Humira.
